Indication
PDAC
6 clinical trials
10 products
3 drugs
Clinical trial
A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)Status: Recruiting, Estimated PCD: 2025-06-01
Product
BMF-219Clinical trial
A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer PatientsStatus: Recruiting, Estimated PCD: 2025-05-01
Product
AMP945Clinical trial
A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsStatus: Recruiting, Estimated PCD: 2027-05-15
Product
RMC-6236Product
mFOLFOX6Drug
bevacizumabProduct
mFOLFIRINOXDrug
cetuximabProduct
gemcitabineDrug
AbraxaneClinical trial
An Exploratory Clinical Study of Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Patients With Locally Advanced Pancreatic CancerStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Randomized Double Blind Study of Pancreatic Enzyme Replacement Therapy for Patients With Metastatic Pancreatic Ductal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-11-30
Product
PertzyeClinical trial
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk IndividualsStatus: Recruiting, Estimated PCD: 2040-10-31
Product
Magnetic Resonance Imaging